To cancel the VHTG indication from the label is futile, the indication will exist independently from Vascepa ('s label) ... however modify the coverage agreements - terminate the VHTG part - is a brilliant step. Let's hope all HCP will do the same. (Assumping it is Amarin's action, plan going forward ... let the 10% of the market for the gV WITHOUT coverage.)
Massulo, Do you or anyone else think it would be a viable strategy to go after every insurance company that is willing to reimburse the cost of gv for the CVD indication? Also do you think this move by United Healthcare is in direct response to the inclusion of Health Net in the infringment suit? Sleven,
IF the HyperTG indication is just short term to reduce the risk for pancreatitis, then the use of Lovaza or fibrates or anything else is fine. IF the reason for chronic long term use is CV event reduction, then the only choice should be Vascepa. HK